20103 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Excipients; Inactive ingredients; Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
PHARMACEUTICAL COMPOSITION HAVING IMPROVED STORAGE STABILITY
#2402SALTS OF ACTIVE INGREDIENTS WITH POLYMERIC COUNTER-IONS
#2403Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
#2404Shell-and-core dosage form approaching zero-order drug release
#2405PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION
#2406TABLET FORMULATIONS COMPRISING VALSARTAN
#2407Candesartan cilexetil
#2408IMPROVED TABLET COATING
#2409Mucosal bioadhesive slow release carrier for delivering active principles
#2410PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION
#2411Bioavailable Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound
#2412Pharmaceutical formulation containing irritant
#2413CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS
#2414Sustained release oral dosage forms of an R-baclofen prodrug
#2415Controlled release matrix pharmaceutical dosage formulation
#2416Stabilized pharmaceutical composition
#2417TOLPERISONE CONTROLLED RELEASE TABLET
#2418COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
#2419Compositions for treating insomnia
#2420METHOD FOR PRODUCING GRANULATED PREPARATION
#2421Solid oral dosage form containing an enhancer
#2422Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
#2423Pharmaceutical compositions
#2424Pharmaceutical compositions comprising hGH for oral delivery
#2425INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA WHICH EXHIBIT AN IN VIVO STAIR-STEPPED ABSORPTION CURVE
#2426Composition for foodstuff for binding acetaldehyde
#2427Misuse preventative, controlled release formulation
#2428Polymer formulations of CETP inhibitors
#2429Highly compactable and durable direct compression excipients and excipient systems
#2430Natural biodegradable matrices and uses thereof
#2431Modified-release formulations of a bupropion salt
#2432Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts
#2433PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE
#2434Crystal Entecavir Formulation And The Preparation Method Thereof
#2435Extended release opioid abuse deterrent compositions and methods of making same
#2436Mixed metal compounds for treatment of hyperphosphataemia
#2437PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLIC ACID OR MYCOPHENOLATE SALT
#2438Oral administration of a calcitonin
#2439SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
#2440Pharmaceutical compositions of duloxetine
#2441GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM
#2442Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
#2443Mixed metal compounds used as antacids
#2444HIGH DRUG LOAD TABLET
#2445MULTILAYERED VITAMIN COMPLEX TABLET CONTAINING UBIDECARENONE
#2446Method of treating diabetes
#2447SLOW RELEASE MISOPROSTOL FOR OBSTETRIC AND/OR GYNAECOLOGICAL APPLICATIONS
#2448PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF CHEWABLE TABLETS AND LOZENGES
#2449TABLETED COMPOSITIONS CONTAINING ATAZANAVIR
#2450TABLETED COMPOSITIONS CONTAINING ATAZANAVIR
#2451PHARMACEUTICAL FORMULATION
#2452Method for the production of a medicament containing tadalafil
#2453Pharmaceutical formulation for the production of rapidly disintegrating tablets
#2454TABLETED COMPOSITIONS CONTAINING ATAZANAVIR
#2455TABLETED COMPOSITIONS CONTAINING ATAZANAVIR
#2456Pharmaceutical formulation for the production of rapidly disintegrating tablets
#2457New Indications for Direct Thrombin Inhibitors
#2458Pharmaceutical formulation for the production of rapidly disintegrating tablets
#2459ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION
#2460SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF
#2461CONTROLLED RELEASE COMPOSITION AND PREPARATION THEREOF
#2462MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS
#2463Therapeutic use of imidazole-5-carboxylic acid derivatives
#2464Pharmaceutical formulation containing gelling agent
#2465Freezable Unit Dosage Delivery System and Method of Preparation
#2466MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES
#2467PHARMACEUTICAL FORMULATIONS OF SEVALAMER, OR SALTS THEREOF, AND COPOVIDONE
#2468Modified release formulations containing drug-ion exchange resin complexes
#2469Confectionery product comprising low molecular weight polyvinyl acetate
#2470Colonic purgative composition with soluble binding agent
#2471Active Agent Formulations, Methods of Making, and Methods of Use
#2472CONTROLLED-RELEASE FORMULATIONS
#2473MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES
#2474Method for stabilizing anti-dementia drug
#2475SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
#2476Formulations for delivering insulin
#2477MODIFIED RELEASE CLOPIDOGREL FORMULATION
#2478NOVEL COMBINED ADMINISTRATION
#2479EXTENDED RELEASE TABLET FORMULATION OF NIACIN
#2480SOLID COMPOSITION COMPRISING A CLAY SUCH AS KAOLIN
#2481Tranexamic acid formulations
#2482PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR
#2483Solid preparation comprising alogliptin and metformin hydrochloride
#2484SUSTAINED RELEASE
#2485Systems for modulating inflammation
#2486USE OF ROSMARINIC ACID IN MANUFACTURE OF MEDICAMENTS FOR TREATING OR PREVENTING HEPATIC AND RENAL DISEASES
#2487Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
#2488Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
#2489Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
#2490Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
#2491MODIFIED RELEASE FORMULATION AND METHODS OF USE
#2492ADDITIONAL THERAPEUTIC USE
#2493STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM
#2494PHARMACEUTICAL COMPOSITION COMPRISING A HOT-MELT GRANULATED LUBRICANT
#2495Process for preparing oral calcium compositions
#2496METHODS OF USING IN SITU HYDRATION OF HYDROGEL ARTICLES FOR SEALING OR AUGMENTATION OF TISSUE OR VESSELS
#2497Dosage form for insertion into the mouth
#2498SURFACE-TREATED MODAFINIL PARTICLES
#2499Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
#2500Tacrolimus for improved treatment of transplant patients
#2501Meltable Binder for Melt Granulation and/or Pelletization
#2502Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
#2503Tamper resistant oral dosage forms containing an embolizing agent
#2504Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
#2505Oral disintegrating tablet
#2506Composition of and Method for Preparing Orally Disintegrating Tablets
#2507COMBINATION WITH AN EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#2508Low dose controlled release tablet
#2509NOVEL STABLE PHARMACEUTICAL COMPOSITIONS OF CLOPIDOGREL BISULFATE AND PROCESS OF PREPARATION THEREOF
#2510Pharmaceutical Composition
#2511PHARMACEUTICAL COMPOSITION
#2512PH SENSITIVE MATRIX FORMULATION
#2513Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics
#2514High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
#2515Anti-diabetic combinations
#2516Pharmaceutical composition and administration thereof
#2517METHOD OF PRODUCING FAST DISSOLVING TABLETS
#2518Oral and injectable formulations of tetracycline compounds
#2519PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT
#2520Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
#2521RELEASE OF STATINS IN THE INTESTINE
#2522HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE
#2523N-ARYL-HYDROXYALKYLIDENE-CARBOXAMIDE COMPOUNDS AND THEIR USE
#2524Stable pharmaceutical composition
#2525Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
#2526Fenofibrate tablets
#2527PHARMACEUTICAL COMPOSITION COMPRISING POROUS DRY MATRIX
#2528PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS
#2529HYDROMORPHONE THERAPY
#2530Solid oral dosage form containing an enhancer
#2531PERORAL SOLID PAIN KILLER PREPARATION
#2532Tablets and Preparation Thereof
#2533FLASHMELT ORAL DOSAGE FORMULATION
#2534Macrocyclic lactone tablet formulation
#2535Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion
#2536Solid dispersions comprising tacrolimus
#2537SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE
#2538Pharmaceutical composition
#2539Controlled-release formulations, method of manufacture, and use thereof
#2540Controlled-release formulations, method of manufacture, and use thereof
#2541Peptide pharmaceutical for oral delivery
#2542ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION
#2543ORGANIC COMPOUNDS
#2544PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT
#2545ATORVASTATIN FORMULATION
#2546ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF
#2547PROCEDURES FOR OBTAINING POLYMERS DERIVED FROM VINYL ACETATE AND THEIR USES
#2548Non-Codeine Opioid Analgesic Process And Formulations
#2549TABLETS WITH IMPROVED DRUG SUBSTANCE DISPERSIBILITY
#2550CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#2551PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT
#2552Direct compression polymer tablet core
#2553MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME
#2554Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
#2555Pharmaceutical formulation for use in hiv therapy
#2556PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION
#2557PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS
#2558PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID
#2559MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
#2560CB-1 receptor modulator formulations
#2561EXTENDED RELEASE DOSAGE FORMS OF QUETIAPINE
#2562MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
#2563COMPOSITION AND METHOD FOR BINDING ACETALDEHYDE IN STOMACH
#2564Method and composition for deterring abuse of opioid containing dosage forms
#2565Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
#2566TABLET FORMULATION
#2567Crystalline forms of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
#2568Taste-masking oral dosage form and method of preparing the same
#2569PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL
#2570QUININE DOSAGE FORMS AND METHODS OF USE THEREOF
#2571Pharmaceutical Compositions Useful in the Treatment of Migraine
#2572SARTAN COMPOSITIONS
#2573STATIN COMPOSITIONS
#2574Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
#2575Pharmaceutical Formulation
#2576Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
#2577Tablet of paracetamol containing an encapsulated flavorant
#2578TRANEXAMIC ACID FORMULATIONS
#2579Solid Formulations
#2580Confectionery Product
#2581TRANEXAMIC ACID FORMULATIONS WITH REDUCED ADVERSE EFFECTS
#2582IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES
#2583DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MAKING SAME
#2584Tranexamic acid formulations
#2585REPAGLINIDE FORMULATIONS
#2586Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
#2587NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2588Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
#2589Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
#2590Pharmaceutical composition
#2591Extended release formulations of guaifenesin
#2592Controlled release hydrocodone formulations
#2593Solid forms containing meloxicam with improved buccal taste and process for their preparation
#2594COMPOSITIONS COMPRISING ALPRAZOLAM FOR TREATING PRIMARY INSOMNIA AND INSOMNIA ASSOCIATE WITH ANXIETY STATES AND PROCESS FOR PREPARING THEM
#2595CONTROLLED RELEASE FORMULATION COMPRISING ANTI-EPILEPTIC DRUGS
#2596BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS
#2597NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2598S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
#2599Disintegrating Loadable Tablets
#2600Utilization of dialkylfumarates
#2601EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#2602Tablet composition containing kampo extract
#2603Utilization of dialkylfumarates
#2604GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
#2605Pharmaceutical compositions and methods for the oral delivery of insulin
#2606Pharmaceutical compositions
#2607Misuse preventative, controlled release formulation
#2608Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
#2609METHODS OF TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES WITH LOW MOLECULAR WEIGHT FUCOIDAN
#2610METHODS OF TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES WITH FUCOIDAN
#2611ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM
#2612Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
#2613Mucosal Bioadhesive SLow Release Carrier for Delivering Active Principles
#2614Oral composition comprising 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionic acid or salt thereof
#2615RALOXIFENE COMPOSITION
#2616Method of manufacturing modified release dosage forms
#2617PHARMACEUTICAL COMPOSITION CONTAINING LEVODOPA, ENTACAPONE AND CARBIDOPA
#2618ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE
#2619SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LUMIRACOXIB
#2620Aminotetralin compounds as mu opioid receptor antagonists
#2621MELT-EXTRUSION MULTIPARTICULATES
#2622Pharmaceutical composition
#2623Controlled release dosage forms
#2624SUSTAINED-RELEASE PREPARATIONS AND METHOD FOR PRODUCING THE SAME
#2625Taste-Masked Tablets and Granules
#2626Composition for the Treatment of Diabetic Periodontitis
#2627Pharmaceutical Compositions of Metformin
#2628SUSTAINED-RELEASE PREPARATION
#2629Pharmaceutical composition comprising licarbazepine acetate
#26305-HT4 partial agonist pharmaceutical compositions
#2631Pharmaceutical Sustained Release Compositions and Processes Thereof
#2632Modified Release Pharmaceutical Compositions and Processes Thereof
#2633Controlled release pharmaceutical compositions
#2634Tamper resistant dosage forms
#2635Pharmaceutical composition containing gelling agent
#2636Process for preparing quetiapine and quetiapine fumarate
#2637Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
#2638Active Agent Formulations, Methods of Making, and Methods of Use
#2639Stable tablet containing droxidopa
#2640Crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
#2641NOVEL CONTROLLED RELEASE-NIACIN FORMULATION
#26421,4-substituted piperazine derivatives
#2643PHARMACEUTICAL FORMULATION USE 030
#2644ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS
#2645PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL
#2646Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Which Exhibit an In Vivo Stair-Stepped Absorption Curve
#2647Saquinavir Mesylate Oral Dosage Form
#2648Sustained release dosage form
#2649Tranexamic acid formulations
#2650Formulations of candesartan
#2651Sustained release composition for oral administration of niacin
#2652Delayed release formulations of 6-mercaptopurine
#2653STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS
#2654Modified Release Formulation
#2655NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2656Fenofibrate compositions
#2657PHARMACEUTICAL FORMULATION
#2658Pharmaceutical composition of telmisartan
#2659Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy
#2660PHARMACEUTICAL COMPOSITIONS COMPRISING MESALAMINE
#2661CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF
#2662Composition Containing Anti-Dementia Drug
#2663ENHANCED FORMULATIONS OF LAMOTRIGINE
#2664Pharmaceutical excipient complex
#2665Drug Forms Having Controlled Bioavailability
#2666Tranexamic acid formulations with reduced adverse effects
#2667Pharmaceutical composition for reducing the area of myocardial infarction and its use
#2668Gastroresistant pharmaceutical formulations containing rifaximin
#2669Pharmaceutical compositions for gastrointestinal drug delivery
#2670Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
#2671Tacrolimus Combination Products
#2672Controlled release and taste masking oral pharmaceutical composition
#2673Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water
#2674Once daily formulations of tetracyclines
#2675Modified release preparations containing oxcarbazepine and derivatives thereof
#2676Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
#2677Method of treating seizures using modified release formulations of oxcarbazepine
#2678Immediate release dosage forms containing solid drug dispersions
#2679CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA
#2680Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization
#2681PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM
#2682Abuse-proof dosage form
#2683Polymer Composition And Dosage Forms Comprising The Same
#2684NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2685Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders
#2686Solid Pharmaceutical Dosage Formulation
#2687Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
#2688Pharmaceutical composition comprising eszoplicone
#2689Direct compression polymer tablet core
#2690Toffee Gum Comprising Chocolate
#2691Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
#2692ZALTOPROFEN-CONTAINING SUSTAINED RELEASE TABLET AND PROCESS FOR THE PREPARATION THEREOF
#2693Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
#2694Pharmaceutical Composition
#2695Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It
#2696CONTROLLED RELEASE DOSAGE FORMS
#2697INJECTION MOULDING PROCESS FOR NEUTRAL AND ACID-GROUP-CONTAINING (METH)ACRYLATE COPOLYMERS
#2698Pharmaceutical Composition
#2699Polymer release system
#2700ORALLY-DISINTEGRATING TABLET AND MANUFACTURING METHOD THEREOF